

Market Announcement

4 October 2021

Atomo Diagnostics Limited (ASX: AT1) – Trading Halt

Description

The securities of Atomo Diagnostics Limited ('AT1') will be placed in trading halt at the request of AT1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 6 October 2021 or when the announcement is released to the market.

Issued by

Alice Montefiore-King

Adviser, Listings Compliance (Sydney)



Level 2, 701 – 703 Parramatta Road
Leichhardt NSW 2040
Australia

+61 2 9099 4750

info@atomodiagnostics.com

4 October 2021

Alice Montefiore-King
Adviser, Listings Compliance
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

cc: tradinghaltssydney@asx.com.au

Dear Ms Montefiore-King,

Request for Trading Halt: Atomo Diagnostics Limited (ASX Code: AT1)

Pursuant to ASX Listing Rule 17.1, Atomo Diagnostics Limited (**Atomo**) requests that a trading halt be granted in respect of its securities pending a market update announcement by Atomo regarding its commercial arrangements with Access Bio Inc (**Announcement**).

Atomo wishes the trading halt to remain in place until the earlier of such time as it makes the Announcement or the commencement of normal trading on Wednesday, 6 October 2021.

Atomo is not aware of any reason why the trading halt should not be granted or of any information necessary to inform the market about the trading halt.

The Managing Director of Atomo has authorised this letter to be given to ASX.

Yours sincerely

Gillian Nairn
Company Secretary